Crucial Radiolabeling Helps Develop ADCs for Cancer Research

Almac has announced it will soon begin providing [¹⁴C] labeling for Antibody Drug Conjugates (ADCs). 

Over the last several years ADCs have been recognized for their ability to effectively treat cancer. Radiolabeling via [¹⁴C] labeling can assist with evaluating the pharmokinetic profile of these ADCs and facilitating absorption, distribution, metabolism, and excretion (ADME) studies. [¹⁴C] labeling is therefore crucial to ADCs further development. The label is generally placed on either the active drug or the linker moiety, or both.

In 2009 the Medicines and Healthcare products Regulatory Agency (MHRA) awarded Almac a license to manufacture a [¹⁴C] radiolabeled drug product. For more information, visit Almac.